Table 4.
OS by de novo and secondary AML
| De novo | Secondary AML | |||
|---|---|---|---|---|
| Glasdegib + LDAC | LDAC alone | Glasdegib + LDAC | LDAC alone | |
| Achieved CR | n = 7 | n = 1 | n = 8 | n = 0 |
| Median OS, months (95% CI) | 14.5 (8.8–26.1) | 12.9 (N/E–N/E) | 34.3 (7.4–N/E) | – |
| Survival probability, % (95% CI) | ||||
| 6 months | 100 (100–100) | 100 (100–100) | 100 (100–100) | – |
| 12 months | 85.7 (33.4–97.9) | 100 (100–100) | 87.5 (38.7–98.1) | – |
| Deaths, n (%) | 6 (85.7) | 1 (100) | 6 (75.0) | – |
| Cause of death: disease under study | 5 (71.4) | 1 (100) | 5 (62.5) | – |
| Did not achieve CR | n = 31 | n = 17 | n = 32 | n = 20 |
| Median OS, months (95% CI) | 4.4 (2.6–6.9) | 3.9 (1.3–8.7) | 7.5 (3.4–9.5) | 4.1 (1.5–6.4) |
| Survival probability, % (95% CI) | ||||
| 6 months | 39.9 (22.1–57.1) | 31.3 (11.4–53.6) | 58.2 (39.1–73.2) | 31.9 (13.1–52.6) |
| 12 months | 29.0 (13.8–46.1) | 12.5 (2.1–32.8) | 25.9 (12.2–41.9) | N/E (N/E–N/E) |
| Deaths, n (%) | 27 (87.1) | 15 (88.2) | 30 (93.8) | 19 (95.0) |
| Cause of death: disease under study | 23 (74.2) | 11 (64.7) | 26 (81.3) | 17 (85.0) |
AML acute myeloid leukemia, CI confidence interval, CR complete remission, LDAC low-dose cytarabine, N/E not evaluable, OS overall survival